Although cures for age-related macular degeneration are elusive, the case for prevention through nutrition looks strong and ...

LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

Key trends include advanced multicolor laser adoption and increased outpatient treatments. Challenges include reimbursement issues and competition from alternative therapies. Leading players like ...

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy ...

The global ophthalmic products market is projected to grow at a CAGR of 5-7% over the next 5 years. Rising cases of vision ...

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding ...

StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin ...

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial ...

Lupin has entered into a licence agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin ...

Lupin partners with SteinCares to commercialize Ranibizumab in Latin America, aiming to improve retinal care access.

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...

Lupin has signed an agreement with SteinCares for the commercialization of biosimilar ranibizumab in Latin America, excluding ...